Cancer
Illumina forms spin-off to develop cancer detection test
January 14, 2016Research and Development Cancer, Illumina, cancer detection, gene sequencing, liquid biospy, oncology
Global gene sequencing company Illumina has won over $100 million in investment from high-profile investors, to create a company “to …
Big pharma joins President Obama’s cancer ‘moonshot’
January 13, 2016Research and Development Amgen, Cancer, Celgene, National Immunotherapy Coalition, President Barack Obama, US, moonshot
Celgene and Amgen are among the large biopharma companies that have agreed to join the National Immunotherapy Coalition (NIC), a …
Novartis expands immuno-oncology programme
January 11, 2016Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology
Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …
PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board
January 7, 2016Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology
Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …
MSD chooses partner to develop ‘game-changing’ cancer therapies
January 6, 2016Research and Development CPABs, Cancer, Cell-Penetrating Alphabodies, Complix, MSD, autoimmune diseases
MSD has entered a research collaboration with biopharma company Complix, using the company’s proprietary technology to develop new treatments for …
100 year old chemical could be the future of cancer treatment
December 23, 2015Research and Development Cancer, PV-10, Peter Culpepper, Provectus, Rose Bengal, oncology
Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …
More breakthroughs in cancer pose the question: Who pays for them?
December 16, 2015Research and Development Cancer, drug access, immunotherapy, oncology
The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …
Researchers launch CAR-T cell therapy trial in head and neck cancer
December 9, 2015Research and Development CAR-T, CAR-T therapy, Cancer, head and neck cancers, oncology R&D
A pioneering trial is beginning in London, where doctors are harnessing patients’ own immune systems to find a new effective …
ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data
December 8, 2015Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology
Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …
Strong cancer trial data for Janssen at ASH 2015
December 8, 2015Research and Development Cancer, Janssen, darzalex, imbruvica, oncology
Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …
Amgen’s Kyprolis doubles Velcade benefit in head-to-head study
December 5, 2015Research and Development, Sales and Marketing Amgen, Cancer, Kyprolis, Takeda, Velcade, multiple myeloma
Amgen has announced that its multiple myeloma therapy Kyprolis displayed superiority to Takeda’s Velcade in the Phase III ENDEAVOR study …
Cancer drugs prices vary up to 388% between high-income countries
December 4, 2015Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology
The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …
NHS England reinstates treatments to Cancer Drugs Fund
November 4, 2015Sales and Marketing Cancer, Cancer Drugs Fund, NHS, NHS England
Five treatments in seven indications have been reinstated to Cancer Drugs Fund, as a result of negotiations between pharma companies …
Sanofi and BioNTech in cancer immunotherapy partnership
November 3, 2015Manufacturing and Production, Research and Development BioNTech, Cancer, Sanofi, immunotherapy
Sanofi and BioNTech have agreed a new multi-year exclusive collaboration and license agreement, to discover and develop up to five …
Otsuka, GW announce Sativex fails in Phase III cancer pain trials
October 28, 2015Research and Development, Sales and Marketing Cancer, GX Pharmaceuticals, Otsuka, Sativex, cancer pain, palliative care, phase III, phase III failure
Otsuka and GW Pharmaceuticals cannabis-based drug Sativex failed to show superiority over placebo in two Phase III trials.The studies were …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
